MX2022006812A - Metodos para tratar epoc mediante la administracion de un antagonista de il-33. - Google Patents
Metodos para tratar epoc mediante la administracion de un antagonista de il-33.Info
- Publication number
- MX2022006812A MX2022006812A MX2022006812A MX2022006812A MX2022006812A MX 2022006812 A MX2022006812 A MX 2022006812A MX 2022006812 A MX2022006812 A MX 2022006812A MX 2022006812 A MX2022006812 A MX 2022006812A MX 2022006812 A MX2022006812 A MX 2022006812A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- antagonist
- administering
- treating copd
- copd
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Se proporcionan los métodos para tratar o prevenir EPOC y condiciones asociadas en un paciente. Se proporcionan los métodos que comprenden administrar a un sujeto en necesidad de la mismo una composición terapéutica que comprende un antagonista de la interleuquina-33 (IL-33), tal como el anticuerpo anti-IL-33 o el fragmento de unión de antígeno del mismo.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962944878P | 2019-12-06 | 2019-12-06 | |
| US202062964966P | 2020-01-23 | 2020-01-23 | |
| US202063082502P | 2020-09-24 | 2020-09-24 | |
| PCT/US2020/063404 WO2021113707A1 (en) | 2019-12-06 | 2020-12-04 | Methods for treating copd by administering an il-33 antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022006812A true MX2022006812A (es) | 2022-08-25 |
Family
ID=74104197
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022006812A MX2022006812A (es) | 2019-12-06 | 2020-12-04 | Metodos para tratar epoc mediante la administracion de un antagonista de il-33. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210230265A1 (es) |
| EP (1) | EP4069365A1 (es) |
| JP (2) | JP7696900B2 (es) |
| KR (1) | KR20220110553A (es) |
| CN (1) | CN114786775A (es) |
| AU (1) | AU2020398168A1 (es) |
| BR (1) | BR112022010934A2 (es) |
| CA (1) | CA3160521A1 (es) |
| IL (1) | IL293544A (es) |
| MX (1) | MX2022006812A (es) |
| TW (1) | TW202134273A (es) |
| WO (1) | WO2021113707A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230169473A1 (en) * | 2020-04-22 | 2023-06-01 | The Board Of Regents Of The University Of Texas System | Medication return platform for extracting value from unused medications |
| WO2025210099A1 (en) * | 2024-04-04 | 2025-10-09 | Medimmune Limited | Method of treatment and selecting a subject |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US8178098B2 (en) | 2001-04-03 | 2012-05-15 | National Jewish Health | Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies |
| PL2374818T3 (pl) | 2006-06-02 | 2013-05-31 | Regeneron Pharma | Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6 |
| SG10201807318RA (en) * | 2013-10-15 | 2018-09-27 | Astrazeneca Ab | Methods for treating chronic obstructive pulmonary disease using benralizumab |
| TWI857389B (zh) * | 2016-12-01 | 2024-10-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
-
2020
- 2020-12-04 CA CA3160521A patent/CA3160521A1/en active Pending
- 2020-12-04 KR KR1020227023070A patent/KR20220110553A/ko active Pending
- 2020-12-04 MX MX2022006812A patent/MX2022006812A/es unknown
- 2020-12-04 AU AU2020398168A patent/AU2020398168A1/en active Pending
- 2020-12-04 BR BR112022010934A patent/BR112022010934A2/pt unknown
- 2020-12-04 CN CN202080084634.3A patent/CN114786775A/zh active Pending
- 2020-12-04 EP EP20830434.5A patent/EP4069365A1/en active Pending
- 2020-12-04 WO PCT/US2020/063404 patent/WO2021113707A1/en not_active Ceased
- 2020-12-04 US US17/112,198 patent/US20210230265A1/en active Pending
- 2020-12-04 JP JP2022533411A patent/JP7696900B2/ja active Active
- 2020-12-07 TW TW109143074A patent/TW202134273A/zh unknown
-
2022
- 2022-06-02 IL IL293544A patent/IL293544A/en unknown
-
2025
- 2025-06-10 JP JP2025096567A patent/JP2025164767A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020398168A1 (en) | 2022-07-28 |
| JP7696900B2 (ja) | 2025-06-23 |
| CN114786775A (zh) | 2022-07-22 |
| BR112022010934A2 (pt) | 2022-11-29 |
| US20210230265A1 (en) | 2021-07-29 |
| TW202134273A (zh) | 2021-09-16 |
| JP2023505215A (ja) | 2023-02-08 |
| JP2025164767A (ja) | 2025-10-30 |
| EP4069365A1 (en) | 2022-10-12 |
| WO2021113707A1 (en) | 2021-06-10 |
| IL293544A (en) | 2022-08-01 |
| KR20220110553A (ko) | 2022-08-08 |
| CA3160521A1 (en) | 2021-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024013963A (es) | Un antagonista de il-4r util para el tratamiento o la prevencion del asma | |
| CY1124298T1 (el) | Φενφλουραμινη για χρηση στην θεραπευτικη αντιμετωπιση του συνδρομου dravet | |
| MX2021013327A (es) | Anticuerpo anti-receptor cgrp para usarse en tratar o prevenir dolor de cabeza por migra?a. | |
| ECSP20046463A (es) | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas | |
| MX2019005617A (es) | Linfocitos infiltrantes de tumores remanentes y metodos de preparacion y uso de los mismos. | |
| EA201491011A1 (ru) | Способы лечения с помощью ингибитора гамма-интерферона | |
| MX2018005315A (es) | Composiciones y metodos para el tratamiento del cancer. | |
| AR092177A1 (es) | Metodos para tratar o prevenir asma administrando un antagonista de il-4r | |
| CO2017004715A2 (es) | Métodos y formulaciones para tratar enfermedades vasculares de los ojos | |
| ECSP18096095A (es) | Anticuerpos a la alfa-sinucleína y usos de los mismos | |
| MX2016000271A (es) | Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r. | |
| MX2022001247A (es) | Metodos para tratar dermatitis atopica mediante la administracion de un antagonista il-4r. | |
| CO2021015793A2 (es) | Métodos para tratar o prevenir el asma mediante la administración un antagonista de il-33 | |
| MX2016013457A (es) | Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo. | |
| MX2022001841A (es) | Anticuerpos contra ilt2 y uso de los mismos. | |
| MX2017000627A (es) | Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe). | |
| MX2021008268A (es) | Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r. | |
| CL2017001756A1 (es) | Régimen de dosificación para antagonistas de madcam. | |
| CL2019001749A1 (es) | Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta. | |
| MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| MX2017011018A (es) | Inhibicion de la actividad de olig2. | |
| MX386249B (es) | Terapia tusc2 para usarse en el tratamiento de cáncer. | |
| MX2022006812A (es) | Metodos para tratar epoc mediante la administracion de un antagonista de il-33. | |
| EA201890623A1 (ru) | Рациональная комбинированная терапия для лечения рака | |
| BR112016023011A2 (pt) | tratamento de câncer gástrico |